



**Uni-Bio Science Appoints Independent Non-executive Director
And Non-executive Director**

* * * *

***Enriches the Board with Greater Industry Insights and Experience in
Developing International Business and Implementing Strategic Alliances***

(Hong Kong, 15 November 2017) – **Uni-Bio Science Group Limited** (“Uni-Bio Science” or the “Group;” HKEx code: 690) has today announced that Mr. Ren Qimin has been appointed as Independent Non-executive Director and Ms. Lau Chau In as Non-executive Director of the Group, effective from [15 November 2017]. The former independent non-executive director Dr. Carl Firth has resigned as Independent Non-executive Director on the same date, in view of other business commitments that require his full time attention. Dr. Carl Firth will continue to act as the Group’s strategy consultant and provide professional advice over corporate development from all aspect. With their assumption of duty, the Board of Directors (“Board”) of the Group is to be enriched with greater industry insight and experience in developing its international business and formulating and implementing strategic alliances.

Mr. Ren has more than 20 years’ experience in executive positions of relations-building within international companies and organisations. He was the Deputy Secretary General and Executive Director of China Association for International Friendly Contact for 10 years. During his tenure, he and his team had helped numerous foreign companies to obtain operating licenses in China and also had arranged more than 150 meetings for the management teams of these companies with senior Chinese government authorities. He was also the Vice President and General Manager of Gallup China, Ltd, a subsidiary of Gallup Inc., USA, the world’s largest polling and market research company, leading it to start its operations in China. In addition, he was working during late 1990s as the Senior Advisor of Government Relations in Beijing with CIGNA Corporation Inc., which is one of the most historical and reputable insurance companies in the USA.

The Group strongly believes that Mr. Ren, with his strong connections with Chinese authorities and rich experience in multinational companies, enables it to build a good relationship with Chinese government departments to develop and consolidate its international and domestic business.

Ms. Lau has graduated with a Bachelor of Business Administration degree from George Washington University in the US. Since graduation, Ms. Lau has played a leading role in the development of HeungKong Healthcare, the healthcare segment of the HeungKong Group. As the general manager, Ms. Lau leads signature projects of HeungKong Healthcare, which include HeungKong Wellness Valley, HeungKong Family Healthcare Center and Tianjin HeungKong Wellness Valley, which focus on elderly care and healthcare operations and provides supplementary light medical products and services. Ms. Lau also actively participates in social and charitable programs. The Group has confidence that with Ms. Lau’s experience in project management and her spirit of entrepreneurship, its strategic alliance with HeungKong Group and with other parties will be more effectively implemented.

Mr. Kingsley LEUNG, Chairman and Executive Director of Uni-Bio Science, said, *“I am delighted with the appointment of the new members of our Board as their proven experience will strengthen our business*

foundation. With them on board, we look forward to achieving promising outcomes for our new product launches and strategic partnerships, as well as realising our goal of becoming a leading internationally recognised bio-pharmaceutical company steadily progressing guided by a broader vision. I am also take this opportunity to express my sincere gratitude to Dr. Carl Firth for his invaluable contribution to the Company during his tenure of office.”

– End –

About Uni-Bio Science Group Limited (SEHK: 0690)

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development centre located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.

Media Enquiries:

Jacob Zhang
Vanco Li

Phone: +86 10 5914 0747
Phone: +86 755 2137 6632

Email: jacob.zhang@uni-bioscience.com
Email: vanco.li@uni-bioscience.com

WeChat ID: Unibio-IR

心 創 造 新 醫 藥
LEADING GENUINE INNOVATION

促進增長 國際視野 Accelerating Growth International Execution

